Search results
Results From The WOW.Com Content Network
Shares of the California-based company fell 16% in extended trading. The decision comes after two failed attempts to secure regulatory approval for the expanded use of pimavanserin in the ...
Acadia had partnered with Biovail in the late-stage clinical testing of the drug, which showed trial failures as of 2009. [ 5 ] [ 6 ] [ 7 ] Acadia is running multiple Phase 2 and Phase 3 trials with pimavanserin in several central nervous system conditions: dementia -related psychosis, [ 8 ] major depressive disorder , [ 9 ] schizophrenia ...
Acadia's drug, trofinetide, to treat Rett syndrome, a genetic brain disorder, was launched in the U.S. last year under the brand name Daybue. "Acadia has misrepresented Daybue's safety profile ...
ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) is possibly approaching a major achievement in its business, so we would... Breakeven On The Horizon For ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Skip ...
In March 2024, Acadia Pharmaceuticals announced its decision to stop any further clinical trials of pimavanserin after the drug did not improve negative symptoms of schizophrenia better than placebo. [ 28 ]
Acadia's stock has fallen on hard times. Is it now a bargain?
Has Wall Street gone a bit overboard punishing ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)? The drug maker’s share price continues to fall Wednesday on the heels of a disappointing 4Q earnings ...
This is a list of companies having stocks that are included in the S&P SmallCap 600 stock market index.The index, maintained by S&P Dow Jones Indices, comprises the common stocks of 600 small-cap, mostly American, companies.